title: Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats.
abstract: The adipokine, leptin, regulates blood glucose and the insulin secretory function of beta cells, while also modulating immune cell function. We hypothesized that the dual effects of leptin may prevent or suppress the autoreactive destruction of beta cells in a virally induced rodent model of type 1 diabetes. Nearly 100% of weanling BBDR rats treated with the combination of an innate immune system activator, polyinosinic:polycytidylic acid (pIC), and Kilham rat virus (KRV) become diabetic within a predictable time frame. We utilized this model to test the efficacy of leptin in preventing diabetes onset, remitting new onset disease, and preventing autoimmune recurrence in diabetic rats transplanted with syngeneic islet grafts. High doses of leptin delivered via an adenovirus vector (AdLeptin) or alzet pump prevented diabetes in>90% of rats treated with pIC+KRV. The serum hyperleptinemia generated by this treatment was associated with decreased body weight, decreased non-fasting serum insulin levels, and lack of islet insulitis in leptin-treated rats. In new onset diabetics, hyperleptinemia prevented rapid weight loss and diabetic ketoacidosis, and temporarily restored euglycemia. Leptin treatment also prolonged the survival of syngeneic islets transplanted into diabetic BBDR rats. In diverse therapeutic settings, we found leptin treatment to have significant beneficial effects in modulating virally induced diabetes. These findings merit further evaluation of leptin as a potential adjunct therapeutic agent for treatment of human type 1 diabetes.
authors.affiliation: Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
authors.forename: Annie J
authors.initials: AJ
authors.lastname: Kruger
authors.forename: Chaoxing
authors.initials: C
authors.lastname: Yang
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Lipson
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Pino
authors.forename: Jean H
authors.initials: JH
authors.lastname: Leif
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Hogan
authors.forename: Barbara J
authors.initials: BJ
authors.lastname: Whalen
authors.forename: Dennis L
authors.initials: DL
authors.lastname: Guberski
authors.forename: Young
authors.initials: Y
authors.lastname: Lee
authors.forename: Roger H
authors.initials: RH
authors.lastname: Unger
authors.forename: Dale L
authors.initials: DL
authors.lastname: Greiner
authors.forename: Aldo A
authors.initials: AA
authors.lastname: Rossini
authors.forename: Rita
authors.initials: R
authors.lastname: Bortell
mesh_terms: D000818:Animals; D001786:Blood Glucose; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000821:virology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D016883:Diabetic Ketoacidosis / Q000517:prevention & control; D006801:Humans; D016381:Islets of Langerhans Transplantation; D020738:Leptin / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D010322:Parvoviridae Infections / Q000276:immunology* / Q000821:virology; D017992:Parvovirus / Q000276:immunology*; D011070:Poly I-C / Q000008:administration & dosage / Q000276:immunology; D051381:Rats; D011913:Rats, Inbred BB; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D020738:Leptin; D011070:Poly I-C